10x Genomics (NASDAQ:TXG) Rating Increased to Strong-Buy at Zacks Research

10x Genomics (NASDAQ:TXG) was upgraded by equities researchers at Zacks Research from a “hold” rating to a “strong-buy” rating in a research report issued to clients and investors on Thursday,Zacks.com reports.

A number of other research analysts have also commented on TXG. Weiss Ratings reiterated a “sell (e+)” rating on shares of 10x Genomics in a research report on Saturday, September 27th. Deutsche Bank Aktiengesellschaft set a $14.00 price objective on 10x Genomics and gave the company a “hold” rating in a research report on Friday, August 8th. Wall Street Zen upgraded 10x Genomics from a “hold” rating to a “buy” rating in a research report on Friday, October 3rd. Piper Sandler assumed coverage on 10x Genomics in a research report on Thursday, September 11th. They issued a “neutral” rating and a $15.00 price objective on the stock. Finally, Bank of America increased their price objective on 10x Genomics from $12.00 to $13.00 and gave the company a “neutral” rating in a research report on Thursday, June 26th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, seven have assigned a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, 10x Genomics presently has an average rating of “Hold” and an average price target of $13.65.

10x Genomics Price Performance

TXG stock opened at $11.47 on Thursday. The business has a fifty day moving average price of $12.98 and a 200 day moving average price of $11.05. 10x Genomics has a fifty-two week low of $6.78 and a fifty-two week high of $18.21. The stock has a market capitalization of $1.43 billion, a price-to-earnings ratio of -16.39 and a beta of 2.05.

10x Genomics (NASDAQ:TXG) last released its quarterly earnings results on Thursday, August 7th. The company reported $0.28 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.35) by $0.63. The firm had revenue of $172.91 million during the quarter, compared to analysts’ expectations of $139.36 million. 10x Genomics had a negative return on equity of 12.88% and a negative net margin of 13.13%.The business’s revenue was up 12.9% on a year-over-year basis. During the same period last year, the firm posted ($0.32) EPS. 10x Genomics has set its Q3 2025 guidance at EPS. On average, equities analysts expect that 10x Genomics will post -1.43 earnings per share for the current fiscal year.

Insider Buying and Selling at 10x Genomics

In other news, CFO Adam Taich sold 22,315 shares of the business’s stock in a transaction on Friday, August 22nd. The shares were sold at an average price of $13.79, for a total value of $307,723.85. Following the completion of the transaction, the chief financial officer owned 309,273 shares of the company’s stock, valued at $4,264,874.67. The trade was a 6.73% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Benjamin J. Hindson sold 7,486 shares of the business’s stock in a transaction on Friday, August 22nd. The shares were sold at an average price of $13.79, for a total transaction of $103,231.94. Following the completion of the transaction, the insider directly owned 440,888 shares of the company’s stock, valued at $6,079,845.52. This trade represents a 1.67% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 39,149 shares of company stock valued at $539,865. Corporate insiders own 9.39% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in TXG. Allworth Financial LP lifted its holdings in 10x Genomics by 150.4% during the second quarter. Allworth Financial LP now owns 2,271 shares of the company’s stock worth $26,000 after acquiring an additional 1,364 shares in the last quarter. GAMMA Investing LLC lifted its holdings in 10x Genomics by 81.8% during the first quarter. GAMMA Investing LLC now owns 3,586 shares of the company’s stock worth $31,000 after acquiring an additional 1,614 shares in the last quarter. Signaturefd LLC lifted its holdings in 10x Genomics by 134.3% during the first quarter. Signaturefd LLC now owns 4,203 shares of the company’s stock worth $37,000 after acquiring an additional 2,409 shares in the last quarter. Whittier Trust Co. bought a new position in 10x Genomics during the first quarter worth about $41,000. Finally, True Wealth Design LLC lifted its holdings in 10x Genomics by 1,552.5% during the second quarter. True Wealth Design LLC now owns 3,586 shares of the company’s stock worth $42,000 after acquiring an additional 3,369 shares in the last quarter. 84.68% of the stock is currently owned by institutional investors.

10x Genomics Company Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.